Novavax says its Covid vaccine is 90% effective, with the company planning to file for authorization with the FDA in the third quarter.
A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020.said Monday its Covid-19 vaccine was shown to be safe and 90.4% effective overall in a phase three clinical trial of nearly 30,000 participants across the United States and Mexico.
The late-stage trial "confirms that NVX-CoV2373 offers an encouraging tolerability and safety profile," Dr. Gregory Glenn, Novavax's president of research and development, said in a press release. "These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus."
The vaccine also appeared to be well-tolerated, according to the company. The most common side effects were fatigue, headache, muscle pain and pain at the injection site, which usually lasted no more than two or three days, the company said.Novavax said the vaccine appears to be effective against some variants, including the Alpha variant, first identified in the U.K. About 65% of the cases where sequence data was available were variants of concern, the company said.
The new data comes as federal officials say the U.S. has more than enough doses of Covid vaccines to finish vaccinating the entire American population. As of Sunday, more than 173 million Americans have had at least one dose of a Covid-19 vaccine, according to data compiled by the Centers for Disease Control and Prevention.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novavax: Large study finds COVID-19 shot about 90% effectiveVaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico. The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said.
Read more »
Novavax COVID-19 vaccine more than 90% effective in U.S. trialNovavax Inc (NVAX.O) on Monday reported late-stage data from its U.S.-based clinical trial showing its vaccine is more than 90% effective against COVID-19 across a variety of variants of the virus.
Read more »
Novavax announces its COVID-19 vaccine is over 90% effective against symptomatic diseaseJUST IN: American biotechnology company Novavax announces that its experimental COVID-19 vaccine is more than 90% effective against symptomatic disease in late-stage clinical trials.
Read more »
Novavax Says Its COVID-19 Vaccine Is Highly Effective In Large StudyWhile demand for COVID-19 shots in the U.S. has dropped off dramatically, the need for more vaccines around the world remains critical.
Read more »
Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trialJUST IN: Novavax says its coronavirus vaccine has an overall efficacy of 90.4% and was 'generally well-tolerated' in a Phase 3 trial in the US and Mexico
Read more »
Novavax Covid vaccine highly effective in U.S. trials, including against variants, company saysNovavax said it plans to apply to the Food and Drug Administration for emergency use authorization in the third quarter.
Read more »